| 
Financial Highlights
(as at 31 December 2010)
| Consolidated Balance Sheets | 2010 | 2009 | |
| RM'000 | RM'000 | ||
| Total non-current assets | 1,017,727 | 953,317 | |
| Total current assets | 992,200 | 1,075,219 | |
| Total assets | 2,009,927 | 2,028,590 | |
| Financed by : | |||
| Share capital | 404,741 | 402,946 | |
| Reserves | 78,752 | 33,134 | |
| Retained profits | 267,637 | 284,389 | |
| Total equity attributable to equity holders of the company | 751,130 | 720,469 | |
| Minority interests | 126,884 | 115,660 | |
| Total equity | 878,014 | 836,129 | |
| Total non-current liabilities | 332,447 | 476,331 | |
| Total current liabilities | 799,466 | 716,130 | |
| Total liabilities | 1,131,913 | 1,192,461 | |
| Total equity and liabilities | 2,009,927 | 2,028,590 | |
| Consolidated Income Statements | 2010 | 2009 | |
| RM'000 | RM'000 | ||
| Turnover | 1,639,039 | 1,571,809 | |
| Profit before taxation | 59,200 | 15,579 | |
| Taxation | (26,129) | (10,511) | |
| Profit after taxation | 33,071 | 5,068 | |
| Minority interests | 17,699 | 10,888 | |
| Profit attributable to shareholders | 15,372 | (5,820) | |
| Group Financial Ratios | 2010 | 2009 | |
| Profitability (%) | |||
| Turnover growth rate | 4.27 | (27.41) | |
| Profit before taxation as a % of turnover | 3.61 | 0.99 | |
| Profit before taxation as a % of shareholders' funds | 7.88 | 2.16 | |
| Liquidity (%) | |||
| Current ratio | 1.24 | 1.50 | |
| Acid test ratio | 0.86 | 0.97 | |
| Market Ratios (%) | |||
| Net assets per share | 1.87 | 1.79 | |
| Earnings per share | 3.80 | (1.44) | |
| Net dividend per share | 2.65 | 8.0 | |
| Productivity | |||
| Turnover per employee (RM) | 809 | 813 | |
| Total Assets per employee (RM) | 993 | 1,049 | |
| Number of employees | 2,025 | 1,934 | |
| # Based on Duopharma's full-year results consolidation | |||
